Vol 14, No 1 (2021)
Review paper
Published online: 2021-09-30

open access

Page views 6000
Article views/downloads 436
Get Citation

Connect on Social Media

Connect on Social Media

Nephrotoxicity of immune checkpoint inhibitors in immunotherapy of oncologic patients

Katarzyna Szychowska, Ilona Kurnatowska12
Renal Disease and Transplantation Forum 2021;14(1).

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 2020; 97(1): 62–74.
  2. Perazella MA, Shirali AC. Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. J Am Soc Nephrol. 2018; 29(8): 2039–2052.
  3. Oleas D, Bolufer M, Agraz I, et al. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Clin Kidney J. 2021; 14(5): 1364–1370.
  4. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron. 2012; 120(4): c179–c184.
  5. Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020; 31(2): 435–446.
  6. Sise ME, Seethapathy H, Reynolds KL. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist. 2019; 24(6): 735–742.
  7. Kostine M, Rouxel L, Barnetche T, et al. FHU ACRONIM. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018; 77(3): 393–398.
  8. Meraz-Muñoz A, Amir E, Ng P, et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020; 8(1).
  9. Malyszko J, Tesarova P, Capasso G, et al. The link between kidney disease and cancer: complications and treatment. Lancet. 2020; 396(10246): 277–287.
  10. Shingarev R, Glezerman IG. Kidney Complications of Immune Checkpoint Inhibitors: A Review. Am J Kidney Dis. 2019; 74(4): 529–537.
  11. Malyszko J, Lee MW, Capasso G, et al. How to assess kidney function in oncology patients. Kidney Int. 2020; 97(5): 894–903.
  12. Brahmer JR, Lacchetti C, Thompson JA, et al. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(17): 1714–1768.
  13. Strohbehn IA, Lee M, Seethapathy H, et al. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. Am J Kidney Dis. 2020; 76(2): 299–302.
  14. Grzejszczak P, Kurnatowska I. Czynniki ryzyka oraz epidemiologia nowotworów u chorych po przeszczepach narządowych. in: Durczyński A, Hogendorf P (red.) Nowotwory po przeszczepieniu narządów. Biblioteka chirurga onkologa. Tom 19. Via Medica Gdańsk. ; 2020: 3–10.
  15. Kumar V, Shinagare AB, Rennke HG, et al. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist. 2020; 25(6): 505–514.
  16. Manohar S, Thongprayoon C, Cheungpasitporn W, et al. Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney Int Rep. 2020; 5(2): 149–158.
  17. Venkatachalam K, Malone AF, Heady B, et al. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients. Transplantation. 2020; 104(5): 1041–1047.



Renal Disease and Transplantation Forum